Clinical trial
A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (5.0 mg or 2.5 mg) of MIN-117 in Adult Patients With Major Depressive Disorder
NCT03446846 is registered in ClinicalTrials.gov with Minerva Neurosciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (5.0 mg or 2.5 mg) of MIN-117 in Adult Patients With Major Depressive Disorder
- Lead sponsor
- Minerva Neurosciences
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 30, 2018
- Completion date
- December 13, 2019
- Enrollment
- 360 (actual)
- Sites
- 47
Conditions
As the registry lists them; a condition with its own page is linked.